AIMS: Recently, we described a series of pancreatic neuroendocrine tumours (PanNETs) featuring prominent stromal fibrosis, which we called sclerosing PanNETs. The aim of this study was to examine the pathological, immunophenotypic and clinical differences between sclerosing and non-sclerosing PanNETs. METHODS AND RESULTS: One hundred and six PanNETs were identified, of which 15 (14%) were sclerosing NETs. Tissue microarrays containing 44 non-sclerosing and five sclerosing PanNETs, as well as sections from 10 additional sclerosing tumours, were immunohistochemically labelled for serotonin, CDX2, CDH17, and islet 1. Sclerosing PanNETs were smaller (P = 0.045) and more likely to show an infiltrative growth pattern (P < 0.001) than non-sclerosing PanNETs. They were frequently associated with a large pancreatic duct, causing duct stenosis. Additionally, we found significantly increased expression of the small intestinal NET markers serotonin, CDX2 and CDH17 in sclerosing PanNETs (P < 0.001) as compared with non-sclerosing PanNETs. No difference in clinical outcome was found; however, more sclerosing PanNETs were stage IIB or above (P = 0.035), with lymph node metastasis being seen in three of nine sclerosing PanNETs with a tumour size of <20 mm. CONCLUSIONS: Sclerosing PanNETs have distinct pathological features and biomarker expression profiles. In addition, lymph node metastasis can be present even with small sclerosing PanNETs.
AIMS: Recently, we described a series of pancreatic neuroendocrine tumours (PanNETs) featuring prominent stromal fibrosis, which we called sclerosing PanNETs. The aim of this study was to examine the pathological, immunophenotypic and clinical differences between sclerosing and non-sclerosing PanNETs. METHODS AND RESULTS: One hundred and six PanNETs were identified, of which 15 (14%) were sclerosing NETs. Tissue microarrays containing 44 non-sclerosing and five sclerosing PanNETs, as well as sections from 10 additional sclerosing tumours, were immunohistochemically labelled for serotonin, CDX2, CDH17, and islet 1. Sclerosing PanNETs were smaller (P = 0.045) and more likely to show an infiltrative growth pattern (P < 0.001) than non-sclerosing PanNETs. They were frequently associated with a large pancreatic duct, causing duct stenosis. Additionally, we found significantly increased expression of the small intestinal NET markers serotonin, CDX2 and CDH17 in sclerosing PanNETs (P < 0.001) as compared with non-sclerosing PanNETs. No difference in clinical outcome was found; however, more sclerosing PanNETs were stage IIB or above (P = 0.035), with lymph node metastasis being seen in three of nine sclerosing PanNETs with a tumour size of <20 mm. CONCLUSIONS: Sclerosing PanNETs have distinct pathological features and biomarker expression profiles. In addition, lymph node metastasis can be present even with small sclerosing PanNETs.
Authors: Takao Hinoi; Peter C Lucas; Rork Kuick; Samir Hanash; Kathleen R Cho; Eric R Fearon Journal: Gastroenterology Date: 2002-11 Impact factor: 22.682
Authors: James C Yao; Milton P Eisner; Colleen Leary; Cecile Dagohoy; Alexandria Phan; Asif Rashid; Manal Hassan; Douglas B Evans Journal: Ann Surg Oncol Date: 2007-09-26 Impact factor: 5.344
Authors: Marco Dioguardi Burgio; Jérome Cros; Nicola Panvini; Thomas Depoilly; Anne Couvelard; Philippe Ruszniewski; Louis de Mestier; Olivia Hentic; Alain Sauvanet; Safi Dokmak; Alex Faccinetto; Maxime Ronot; Valérie Vilgrain Journal: Eur Radiol Date: 2021-05-11 Impact factor: 5.315
Authors: Motoyo Yano; Anup S Shetty; Greg A Williams; Samantha Lancia; Nikolaos A Trikalinos; Chet W Hammill; William G Hawkins; Amber Salter; Deyali Chatterjee Journal: Abdom Radiol (NY) Date: 2022-02-15
Authors: Zijie Feng; Xin He; Xuyao Zhang; Yuan Wu; Bowen Xing; Alison Knowles; Qiaonan Shan; Samuel Miller; Taylor Hojnacki; Jian Ma; Bryson W Katona; Terence P F Gade; Jörg Schrader; David C Metz; Carl H June; Xianxin Hua Journal: Nat Cancer Date: 2022-03-21
Authors: Andreas Selberherr; Oskar Koperek; Philipp Riss; Christian Scheuba; Reto Kaderli; Aurel Perren; Bruno Niederle Journal: Endocr Pathol Date: 2019-03 Impact factor: 3.943